Revenue Cycle Management in India: How the Industry Works and Where It Is Going
SRF Capital Studio Research DeskFunding Intelligence, SRF Capital StudioRevenue cycle management is the chain of work that turns a hospital visit into cash. India runs much of it for American hospitals and is only starting to build it for its own.
Summary
- Revenue cycle management is every step between a patient's first contact and the last rupee or dollar collected, and India is one of the world's largest delivery centres for it on behalf of US providers.
- The export business is consolidating fast under global private equity, while the domestic market is being forced into shape by insurance growth, PM-JAY and new claims rules.
- Value sits in the judgement-heavy stages (coding, documentation, denials) and in data; the rule-following stages are being automated, and vendors priced on headcount there will be squeezed.
Most people meet revenue cycle management from the wrong end. A patient sees a bill. A hospital promoter sees a receivables number that never seems to shrink. An investor sees a services company with thousands of employees in Chennai or Navi Mumbai and files it under BPO.
All three are looking at the same machine. This report explains how it works, why India holds such an odd position in it, where the money is made and lost, and what founders, investors and hospital finance teams should do about it. It is the anchor for a series; six shorter pieces each take one angle further, and we link to them as we go.
What revenue cycle management is
A hospital earns revenue the moment it treats someone. It collects that revenue weeks or months later, and only if a long list of things goes right in between. Revenue cycle management (RCM) is the discipline of making that list go right: capturing who the patient is and who pays, recording what was done, translating it into the codes and forms a payer accepts, chasing the payment, fighting the refusals and closing the account.
It is wider than billing. Billing is the act of raising a claim. RCM covers the work before it (registration, eligibility checks, pre-authorisation, clinical documentation) and the work after it (posting payments, managing denials, following up on unpaid accounts, collecting what the patient owes).
The payoff is simple to state. A hospital with weak RCM has already done the clinical work and paid for the staff, drugs and consumables. What it loses to missed charges, wrong codes and unappealed rejections is margin it earned and never banked.
RCM is not a cost-saving function. It is the part of the hospital that decides how much of the revenue it has already earned actually arrives.
The stages, one at a time
Different practitioners split the cycle into seven, nine or twelve steps. The split below is the one we find most useful because each stage has a different owner, a different failure mode and a different answer to the question of whether software or people should do it.
The revenue cycle, stage by stage
| Stage | What happens | Typical failure | Who does it best |
|---|---|---|---|
| Patient access | Registration, identity, payer details, appointment | Wrong policy or member ID captured at the desk | Software, with a trained front desk |
| Eligibility and pre-authorisation | Confirm cover, limits and approvals before treatment | Treatment given without approval, or beyond the sum insured | Mostly automatable through payer portals and APIs |
| Charge capture | Every drug, consumable and procedure recorded against the patient | Items used but never billed | Integrated hospital software plus audit |
| Clinical documentation | Doctor's notes that support the diagnosis and severity | Vague notes that justify a lower-paying code | Specialists who query doctors |
| Medical coding | Notes translated into ICD-10 diagnosis and procedure codes | Undercoding (lost revenue) or overcoding (compliance risk) | Certified coders, increasingly with AI suggestions |
| Claim submission | Claim assembled, checked against payer rules, sent | Missing fields, wrong format, late filing | Rules engines |
| Payment posting | Remittances matched to claims and accounts | Short payments posted as full | Largely automated |
| Denial management | Rejections sorted, corrected, appealed, root causes fixed | Denials written off because nobody appealed in time | Analysts with payer-specific knowledge |
| Follow-up and patient collections | Unpaid claims chased; patient share collected | Accounts ageing past the point of recovery | Prioritised teams, part automated |
Two patterns matter more than any single row. First, errors made early are paid for late: a wrong policy number typed at registration becomes a denial six weeks later, and it costs far more to fix then. Second, the stages split cleanly into those that follow rules and those that need judgement. That split decides where automation wins and where margin survives.
For the reader who wants the stage economics in detail, our value-chain piece on denial management walks through where each stage makes or loses money.
A worked example: one Indian hospital's cycle
Numbers make the stages concrete. The example below is illustrative, not drawn from a client: a 150-bed private hospital billing ₹60 crore a year, with 55% of revenue from private insurers and TPAs, 20% from government schemes and 25% from patients paying directly.
That gives ₹45 crore a year passing through a payer. Suppose the hospital's insurers and TPAs deduct 10% of the amount claimed, somewhat better than the 12.9% industry figure IRDAI reported for 2023-24. That is ₹3.3 crore on the private book alone. Some of those deductions are contractual and fair; many are for items the hospital could have documented, pre-authorised or coded correctly.
Now add time. If scheme and TPA payments take 90 days to arrive rather than 45, the hospital carries roughly an extra 45 days of that ₹45 crore on its balance sheet, about ₹5.5 crore of working capital it has to fund with debt or promoter money.
What a weak revenue cycle costs a ₹60 crore hospital (illustrative)
| Line | Illustrative value |
|---|---|
| Annual billing | ₹60 crore |
| Share billed to insurers, TPAs and schemes | 75%, or ₹45 crore |
| Private insurer and TPA deductions at 10% of ₹33 crore | ₹3.3 crore a year |
| Recovered if half of avoidable deductions are fixed (assume two-thirds avoidable) | About ₹1.1 crore a year |
| Extra working capital tied up at 90 rather than 45 days | About ₹5.5 crore |
A crore a year of recovered margin and five crore of released cash is a larger number than most hospitals of this size earn in net profit. It explains why the domestic market exists at all, and why the vendors that win it sell recovered rupees rather than processing capacity.
One industry, two very different markets
When an Indian investor hears "RCM company", it usually means one of two businesses that share a name and very little else.
The export industry
The first is India's offshore RCM industry, which works almost entirely for US hospitals, physician groups and insurers. The American system is the most administratively complex in the world: thousands of payer plans, each with its own rules; Medicare and Medicaid; annual code updates; prior-authorisation regimes that differ plan by plan. US providers have spent two decades moving coding, billing, follow-up and denial work to India because it is cheaper, the talent pool is deep and the time difference allows overnight turnaround.
The largest Indian-origin operators employ tens of thousands. Omega Healthcare reports more than 30,000 people across 14 delivery centres in the US, India, Colombia and the Philippines. GeBBS reports around 13,000. AGS Health, based in Chennai, reports over 12,000 and more than 150 US hospital and health-system clients. MarketsandMarkets puts India's healthcare BPO market at about USD 11.35 billion in 2025, growing at 13.8% a year to 2030; treat that as a consultancy estimate, but the order of magnitude is consistent with what the listed and filing companies disclose.
Our piece on India's healthcare BPO market covers the export side in depth.
The domestic market
The second business is RCM for Indian hospitals, and it looks nothing like the first. Payers are fewer but messier: private insurers and their TPAs, PM-JAY and state schemes, CGHS and ECHS, corporate tie-ups, and a large self-pay share. Tariffs are often package rates rather than itemised bills, which moves the fight from coding to documentation and deductions.
The domestic buyer is also different. A 150-bed promoter-run hospital in a tier-2 city does not buy a coding team. It buys fewer disallowances, faster TPA settlements and a receivables book that stops growing. The vendor that wins here sells software, process and a few trained people, often bundled with the hospital information system.
The domestic market is younger and much smaller in rupees, but the forces pulling it forward are real and, for once, measurable.
The size of the market, and why the estimates disagree
There is no agreed number for the size of RCM, globally or in India, and anyone quoting one to three significant figures should be asked what it includes.
Globally, Precedence Research puts the RCM market at about USD 170 billion in 2025. Grand View Research puts the US market alone at about USD 190 billion for the same year. Both can be right only because they are measuring different things: one counts software and outsourced services, the other appears to count a much larger share of the in-house cost of running revenue cycles. The honest reading is that US providers spend well over a hundred billion dollars a year on getting paid, and that a fast-growing slice of that spend is outsourced.
For India's domestic market the spread is worse. Published estimates for "India RCM" range from a few hundred million dollars to more than USD 5 billion, depending on whether they include export work done in India. We do not repeat any single figure. Precise rupee market sizes and segment maps circulate in industry presentations; we could not find a primary source for any of them.
What can be measured is the claim volume that domestic RCM has to process:
- Insured lives. IRDAI's annual report for 2024-25 records 58.20 crore lives covered by health insurance and health premiums of ₹1,17,505 crore. Every insured admission is a claim that has to be documented, submitted and settled.
- PM-JAY. The National Health Authority reports 12.69 crore hospital admissions worth ₹1.92 lakh crore authorised under Ayushman Bharat PM-JAY up to 30 June 2026, across 32,574 empanelled hospitals, of which 15,532 are private (December 2025 count).
- Deductions and rejections. IRDAI data for 2023-24 showed insurers disallowed claims worth about ₹15,100 crore, 12.9% of the amount claimed, on top of outright repudiations. That money is the domestic equivalent of a US denial pool.
- Rules with clocks on them. IRDAI's master circular of May 2024 requires insurers to decide cashless requests within one hour and final discharge authorisation within three. A hospital that cannot send clean documents in that window absorbs the delay itself.
- A national claims exchange. The National Health Claims Exchange went live in June 2024 to move claims between hospitals, insurers and TPAs in a standard digital format. reports put onboarded hospitals above 12,600 by mid-2026.
Put together, these point to a domestic market that is small in vendor revenue today and large in the problem it addresses. The payer side has digitised faster than the provider side, and the gap is where domestic RCM vendors sell. Our earlier analysis of hospital payer mix and package rates shows how those disallowances land in a hospital's P&L.
The economics of an RCM business
An RCM services company is a people business with a software layer. The largest cost is trained labour: coders, documentation specialists, denial analysts, follow-up teams. Technology, facilities, compliance and sales sit on top. That structure has three consequences that shape everything else.
Margin follows the work mix, not the client count. A contract to post payments or check eligibility is priced per transaction and competes with software that does the same job. A contract to code complex inpatient charts or to recover denied claims is priced on expertise or outcome. The same company can run both, and the blended margin tells you which way it is drifting.
Scale helps only when productivity rises. Adding a hospital client usually means adding people. Operating gains appear when tools let each coder or analyst handle more work, when attrition falls, or when onboarding a new client gets faster. A vendor that grows revenue and headcount at the same rate is not scaling; it is getting bigger.
Working capital is quietly heavy. Clients pay monthly in arrears, and outcome-based fees arrive only when the payer does. A fast-growing vendor can be profitable and short of cash at the same time.
What the listed numbers say
Two companies give the market something better than estimates. Sagility, which serves US payers and providers, listed in November 2024 after a ₹2,106.6 crore IPO. For the fourth quarter of FY25 it reported revenue of ₹1,568.5 crore and adjusted of ₹383.2 crore, a margin of about 24%. AGS Health's updated draft prospectus, filed with in August 2026, shows FY26 consolidated revenue of ₹2,041.4 crore and profit of ₹206.9 crore, a net margin near 10%, carried alongside borrowings of ₹4,238.8 crore from its buyout.
Neither is a clean benchmark for a ₹100 crore domestic vendor. They are useful for a different reason: they show that a scaled Indian RCM operator can earn a healthy operating margin, and that debt from private- ownership can consume a large part of it.
The margin ladder
Across the industry, practitioners describe a consistent ordering even where they disagree on the exact percentages. Payment posting, eligibility checks and basic claim submission earn the least and are automating fastest. Follow-up on unpaid accounts sits in the middle. Coding, clinical documentation improvement and outcome-priced denial recovery earn the most, because they rely on certified judgement and payer knowledge that accumulates over years and does not move easily to a new vendor.
Industry presentations often assign precise gross and EBITDA margins to each stage. We do not repeat them because we could not trace them to a source. The ordering is the useful part, and it holds up in every conversation we have had with operators.
The numbers that tell you whether a revenue cycle works
A hospital, a vendor and an investor should all be looking at the same handful of indicators. We cover them properly, with formulas and rupee examples, in the RCM KPI guide. The short version:
- Days in accounts receivable. How many days of revenue are sitting uncollected. HFMA's benchmarking treats roughly 30 to 60 net days as the normal range for US providers; many Indian hospitals with heavy scheme and TPA exposure run far longer.
- Clean claim rate. The share of claims that pass every edit without manual touch. HFMA's MAP Keys use 95% as the reference point.
- Initial denial rate. Kodiak Solutions, drawing on more than 2,100 US hospitals, reported 11.81% of claims initially denied in 2024, up from about 10.2% in 2020. Only 2.8% were finally written off, which is the case for denial work in one number.
- Disallowance rate (India). The share of claimed amount an insurer or TPA deducts. It is the metric Indian hospitals most often do not track by payer.
- Cost to collect. What the hospital spends, in-house and outsourced, to collect each rupee.
Who is winning, and the deals that show it
The export industry has been re-priced by private equity in the last two years. Almost every scaled Indian-origin operator has changed hands or filed for a listing since 2024.
Selected transactions in Indian-origin healthcare RCM, 2024 to 2026
| Company | Transaction | Date | Reported value |
|---|---|---|---|
| GeBBS Healthcare Solutions | Eqt (bpea Fund VIII) buys control from ChrysCapital | Sep 2024 | About USD 850-870 million |
| Sagility | IPO on NSE and BSE | Nov 2024 | ₹2,106.6 crore raised |
| Vee Healthtek | TA Associates takes majority stake; Valliappa family retains minority | Nov 2024 | About USD 250 million |
| Omega Healthcare | Ontario Teachers' takes co-control stake alongside Goldman Sachs Alternatives | Dec 2024 | Not disclosed |
| Access Healthcare | New Mountain Capital takes majority stake | Jan 2025 | About USD 2 billion valuation |
| Access Healthcare | Combined with SmarterDx and Thoughtful.ai as Smarter Technologies | May 2025 | Combined revenue above USD 800 million |
| AGS Health | Blackstone buys from an EQT-managed Baring Asia fund | 2025 | About USD 1.4 billion |
| AGS Health | Updated draft prospectus for IPO | Aug 2026 | Up to ₹4,800 crore issue |
In the US, the same logic played out at a larger scale: TowerBrook and Clayton, Dubilier & Rice took R1 RCM private for about USD 8.9 billion in November 2024. R1 runs large Indian delivery centres, so the deal is part of the same story.
Three things explain the rush. Demand is not discretionary; providers cannot stop billing. US initial denial rates rose from about 10.2% in 2020 to 11.8% in 2024, which increases the work per claim. And the Indian operators had reached a size where a buyer could fund AI tooling and bolt-on acquisitions across a single platform. Our piece on RCM companies in India and the investment case takes each deal apart.
What sets the winners apart is not size alone. Across the deals, the assets that commanded attention had four things: long contracts with large US health systems, a meaningful share of higher-judgement work (documentation, complex coding, denial recovery), security certifications US buyers require, and a credible AI story that raised output per employee rather than just claims about it.
Where the industry is heading
AI changes the price of routine work first
Tools that suggest codes from clinical notes, read remittance files and draft appeal letters are already in production. They cut the labour needed for routine outpatient coding and for most of the rule-following stages. The work that resists them is inpatient coding for patients with several conditions, documentation queries to doctors and payer-specific appeals, where the answer depends on clinical reasoning and on how a particular payer behaves.
Vendors quote precise AI accuracy rates and adoption timelines. We have not repeated them; vendor-reported accuracy varies with case mix and is rarely audited. The direction is not in doubt. Clients will ask for the productivity gain to be passed through in price, and vendors whose revenue is mostly routine coding billed per chart will see rates fall.
AI does not remove the RCM vendor. It removes the vendor's excuse for pricing by headcount.
Domestic formalisation is policy-driven
In India, the push is coming from payers and regulators rather than from hospitals. PM-JAY's volume, the one-hour and three-hour clocks, the claims exchange and insurers' own digitisation all reward hospitals that send complete, coded, well-documented claims and penalise those that do not. Mid-size hospitals feel this first because they have enough insured volume to hurt and too little finance staff to cope.
That is the opening for domestic vendors, and it favours software-plus-service models priced on outcomes (lower disallowances, faster settlement) over headcount sold by the seat. It is also why hospital information system vendors are natural competitors: they already hold the data.
Consolidation continues in the middle
Below the private-equity-owned leaders sits a long tail of mid-size export vendors, many founder-run, with ₹50 to ₹300 crore of revenue and a few anchor clients. They face higher wage bills, clients asking for AI pricing, and larger rivals able to bundle services. Some will specialise, some will be bought, and some will stall. Our growth strategy piece for RCM operators sets out the choices.
Risks
- Pricing pressure from automation. The most certain risk. It is manageable for vendors who move their mix toward judgement work, and severe for those who do not.
- Data protection. India's Digital Personal Data Protection Rules were notified in November 2025, with full obligations applying from May 2027. Failure to keep reasonable security safeguards can attract penalties up to ₹250 crore. RCM vendors hold health and financial data on millions of patients; US clients add their own HIPAA-driven audits.
- Client concentration. Many mid-size export vendors earn most of their revenue from a handful of US systems. One lost renewal can erase a year's growth, and buyers price that in.
- Talent and attrition. Certified coders and experienced denial analysts are in demand across the industry. Attrition raises training costs and lowers accuracy on client accounts.
- US policy. Changes to Medicare Advantage, prior-authorisation rules or offshoring restrictions for government programmes can shift the volume and nature of US work quickly.
- Debt. Buyouts have loaded several leaders with debt. AGS Health's filing, which proposes using most of its fresh issue to repay borrowings, is a reminder that a strong operating business can still be constrained by its capital structure.
One risk we think is commonly overstated: that AI will make the sector uninvestable. The more realistic outcome is a split, with routine work cheapening and judgement work holding value, which rewards mix management rather than avoidance.
What to do
If you are building an RCM company
- Decide which market you are in. Export and domestic RCM need different sales motions, compliance and pricing, and trying to do both early usually means doing neither well.
- Report your revenue mix by stage to your own board every quarter. If routine work is growing faster than judgement work, your margin will fall before your revenue does.
- Price at least one service on outcome. Denial recovery and disallowance reduction are the natural candidates, and outcome pricing forces you to measure yourself.
- Treat security certification and data-protection compliance as sales infrastructure, not overhead.
If you are investing
- Ask for client-level retention, revenue per employee and mix by service line for three years. A flat revenue-per-employee line under a growing top line is the warning sign.
- Test AI claims against output per coder, not against demos.
- Look at the top five clients' contract terms and renewal dates before you look at the growth rate. Our due diligence practice starts there for services businesses.
If you run a hospital's finance function
- Measure disallowances by payer and by reason for one quarter before you buy anything. Most hospitals that do this find two or three fixable causes behind most of the loss.
- Buy outcomes, not seats. A vendor who will not commit to a disallowance or settlement-time target is selling labour.
- Link RCM to the rest of the revenue system. How we think about that across pricing, payer mix and collections is set out in RevenueOS for hospitals and diagnostics.
Where we disagree with the common story
Three claims recur in RCM pitch decks and industry commentary, and we think each is wrong or overstated.
"India does 40% of the work and keeps 6% of the value." We could not find a source, and the listed numbers suggest scaled Indian operators earn margins comparable to many US services firms. The real gap is narrower: Indian vendors are under-represented in RCM software and payer analytics, where the highest valuations sit.
"The domestic market will grow at 25% a year." Claim volume is growing fast, but hospitals' willingness to pay outside vendors is not growing at the same rate. Domestic RCM will be won by vendors that can prove recovered rupees within a quarter, and that is a slower sale than the forecasts assume.
"AI will replace coders." It will replace a large share of routine coding hours. It will also make a smaller number of experienced coders and analysts more valuable, and it will move pricing power to whoever owns the data on how payers behave.
Method and sources
This report was written by SRF Capital Studio's research desk in September 2026. Every figure was checked against the sources below, and figures commonly quoted in the industry that we could not trace to a source were left out. Market-size estimates from research vendors are presented as estimates, with their publisher named. Currency is rupees for Indian data and US dollars for US and global data and for deal values reported in dollars.
- IRDAI, Annual Report 2024-25, and IRDAI data on health claims for 2023-24 as reported by Business Standard
- IRDAI, Master Circular on Health Insurance Business, 29 May 2024
- National Health Authority, PM-JAY statistics to 30 June 2026 and empanelment data to 1 December 2025
- National Health Claims Exchange programme information and secondary reporting on onboarding, 2026
- Ministry of Electronics and IT, Digital Personal Data Protection Rules, 2025 (notified 14 November 2025)
- Kodiak Solutions, revenue cycle benchmark data on 2024 claim denials (May 2025)
- Hfma, map Keys revenue cycle benchmarks
- Precedence Research and Grand View Research, revenue cycle management market estimates, 2025
- MarketsandMarkets, India healthcare BPO market estimate, 2025-2030
- EQT, ChrysCapital and GeBBS press releases (September 2024); Reuters reporting on deal value
- TA Associates and Vee Healthtek press releases (November 2024)
- Ontario Teachers' Pension Plan and Omega Healthcare press releases (December 2024)
- New Mountain Capital press releases on Access Healthcare (January 2025) and Smarter Technologies (May 2025)
- AGS Health updated (August 2026), as reported by Outlook Business and others; reporting on the Blackstone acquisition (2025)
- Sagility India IPO documents (November 2024) and Q4 FY25 results (May 2025)
- R1 RCM, TowerBrook and CD&R announcements on completion of the take-private (November 2024)
How useful was this article?
One tap. It tells us what to write more of.
About the author
SRF Capital Studio Research Desk
Funding Intelligence, SRF Capital Studio
The next one
Get what we publish next, by email.
Working notes on raising, borrowing, protecting, growing and structuring capital in India. One email a week at most, and you can leave any time.
We use your address only to send this. See our privacy policy.
We store your address to send you these emails and nothing else. See our privacy policy.
Related reading